How Ruijin Hospital Is Leading CAR-T Cell Therapy and Cancer Care for Overseas Patients

Over the past decade, immunotherapy has reshaped the way cancer is treated worldwide. Among the most promising breakthroughs is CAR-T cell therapy, a treatment that uses a patient’s own immune cells to attack cancer. As demand for this advanced therapy grows, more international patients are exploring treatment options beyond their home countries.

One institution gaining global attention is Ruijin Hospital in Shanghai. Known for its strong research culture and high-level clinical expertise, Ruijin Hospital has become one of the leading centers in Asia offering CAR-T cell therapy and comprehensive cancer care for overseas patients.

Below is a closer look at how the hospital is positioning itself at the forefront of this rapidly evolving field.

A Pioneer in CAR-T Cell Therapy in Asia

CAR-T cell therapy—short for Chimeric Antigen Receptor T-cell therapy—represents a new generation of personalized cancer treatment. Instead of relying solely on chemotherapy or radiation, doctors modify a patient’s T-cells in a laboratory so they can recognize and destroy cancer cells more effectively.

At Ruijin Hospital, CAR-T therapy is primarily used for certain blood cancers, including:

Relapsed or refractory leukemia

Aggressive lymphoma

Multiple myeloma in selected cases

The hospital’s hematology department is widely respected in China and across Asia for its deep experience in complex blood diseases. With years of clinical trials and translational research, the team has helped move CAR-T therapy from experimental science into real-world clinical treatment.

For international patients who may have exhausted standard therapies at home, this offers an important new option.

Integrated Cancer Care Under One Roof

One reason overseas patients are drawn to Ruijin Hospital is the hospital’s multidisciplinary cancer treatment model.

Rather than seeing specialists separately, patients benefit from a coordinated care team that may include:

Hematologists

Medical oncologists

Immunotherapy specialists

Radiologists

Pathologists

Genetic testing experts

This collaborative approach ensures that every patient receives a personalized treatment strategy based on the biology of their disease.

For complex cancers—especially those that have resisted previous treatments—this kind of team-based decision-making can significantly improve treatment planning.

Strong Research Backed by a Leading Medical University

Ruijin Hospital is affiliated with Shanghai Jiao Tong University School of Medicine, one of the country’s most prestigious medical schools.

This academic connection plays a critical role in advancing cancer treatment. Physicians at the hospital are not only clinicians—they are also researchers involved in:

CAR-T cell engineering

Tumor immunology

Clinical trials for emerging therapies

Precision oncology

Because of this close link between laboratory science and patient care, many therapies become available to patients earlier than they might in traditional hospital settings.

For overseas patients seeking cutting-edge cancer treatment, access to a research-driven medical environment can be a major advantage.

Precision Medicine and Advanced Diagnostics

Another key strength of Ruijin Hospital’s cancer program is its focus on precision medicine.

Before determining the best treatment plan, doctors often perform advanced diagnostic testing, such as:

Genetic mutation analysis

Tumor biomarker testing

Immune profiling

Next-generation sequencing (NGS)

These tools allow physicians to better understand how a particular cancer behaves and which treatments are most likely to work.

In many cases, this information helps determine whether CAR-T therapy—or another targeted treatment—will offer the greatest benefit.

Why Overseas Patients Are Looking to Shanghai

Medical travel for cancer treatment is increasing worldwide. Several factors make Shanghai an attractive destination for international patients.

Access to advanced therapies

Some immunotherapy approaches and clinical trials may be available sooner in certain global medical centers.

Experienced specialists

China treats a very large number of cancer patients each year, giving leading hospitals significant clinical experience.

Cost advantages

Even advanced treatments can sometimes be more affordable compared with hospitals in North America or parts of Europe.

International infrastructure

Shanghai is one of Asia’s most international cities, offering convenient flights, modern medical facilities, and growing international patient services.

Support Services for International Patients

Recognizing the growing demand for global healthcare services, Ruijin Hospital has been expanding support for international patients.

These services may include:

Medical consultation coordination

International patient departments

Assistance with travel planning

Multilingual communication support

Post-treatment follow-up planning

Such services are especially important for patients traveling long distances for complex therapies like CAR-T treatment.

The Future of Cancer Immunotherapy at Ruijin Hospital

The field of cancer immunotherapy is evolving rapidly. CAR-T therapy is already transforming treatment for certain blood cancers, and research is now expanding into solid tumors, which represent the majority of cancer cases worldwide.

Clinicians and scientists at Ruijin Hospital are actively exploring next-generation immunotherapies, including:

Improved CAR-T designs

Combination immunotherapy strategies

New cellular therapies beyond CAR-T

Personalized cancer vaccines

As these innovations move forward, the hospital is expected to remain a key player in shaping the future of cancer treatment in Asia.

A Growing Destination for Global Cancer Care

For overseas patients facing difficult cancer diagnoses, access to advanced therapies can make a life-changing difference. With its strong hematology expertise, commitment to research, and integrated cancer care model, Ruijin Hospital is increasingly recognized as a leading destination for CAR-T cell therapy and modern oncology treatment.

As international medical travel continues to expand, institutions that combine scientific innovation with patient-centered care—like Ruijin Hospital—are likely to play a growing role in the global fight against cancer.

Document dated 2026-03-11 15:18 Modify